Drug Profile
Research programme: schistosomiasis therapeutic - LondonPharma
Alternative Names: Artemisinin-based schistosomiasis therapeutic - LondonPharma; Schistosomiasis repurposed therapeutic - LondonPharmaLatest Information Update: 06 Aug 2023
Price :
$50
*
At a glance
- Originator LondonPharma
- Class Artemisinins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Schistosomiasis
Most Recent Events
- 06 Aug 2023 Discontinued - Preclinical for Schistosomiasis in United Kingdom (Sublingual)
- 28 Dec 2018 No recent reports of development identified for preclinical development in Schistosomiasis in United Kingdom (Sublingual, Spray)
- 18 Nov 2014 Preclinical trials in Schistosomiasis in United Kingdom (Sublingual)